CatalYm GmbH
- Country
- 🇩🇪Germany
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.catalym.com
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A multi-center Phase 2 study of neoadjuvant immunotherapy in combination with the anti-GDF-15 antibody visugromab (CTL-002) for the treatment of muscle invasive bladder cancer
- Conditions
- Muscle invasive bladder cancer set to undergo radical cystectomy who cannot receive or refuse to receive cisplatin-based chemotherapy
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- CatalYm GmbH
- Target Recruit Count
- 30
- Registration Number
- 2024-513957-55-00
- Locations
- 🇮🇹
Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino, Turin, Italy
🇮🇹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
🇮🇹Azienda Ospedaliera Ordine Mauriziano Di Torino, Turin, Italy
First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)
- Conditions
- Solid Tumor, Adult
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- CatalYm GmbH
- Target Recruit Count
- 274
- Registration Number
- NCT04725474
- Locations
- 🇩🇪
Universitätsklinikum Essen, Westdeutsches Tumorzentrum, Innere Klinik und Poliklinik, Essen, Germany
🇩🇪Universitätsklinikum Frankfurt, Medizinische Klinik I, Frankfurt am Main, Germany
🇩🇪Universitätsklinikum Würzburg, Comprehensive Cancer Center, Würzburg, Germany
News
CatalYm's Visugromab Shows Promise in Enhancing Antibody-Drug Conjugate Efficacy by Blocking GDF-15
New preclinical data reveals that visugromab, CatalYm's GDF-15-neutralizing antibody, significantly enhances the anti-tumor activity of antibody-drug conjugates (ADCs) in multiple solid tumor models.